Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclophosphamide Sandoz is a branded generic version of cyclophosphamide, a nitrogen mustard alkylating agent and potent immunosuppressant. As a prodrug, it is metabolically activated by hepatic cytochrome P450 enzymes, primarily CYP2B6, into active metabolites such as phosphoramide mustard. This active form creates interstrand and intrastrand DNA cross-links at the N-7 position of guanine, which inhibits DNA replication and triggers apoptosis in rapidly dividing cells, including lymphocytes. While traditionally used as a chemotherapy agent for various malignancies like lymphomas and leukemias, its immunosuppressive properties are leveraged in the treatment of severe autoimmune conditions and paraneoplastic syndromes. Specifically, Assistance Publique Hopitaux De Paris has investigated its use in treating paraneoplastic sensory neuropathy associated with anti-Hu antibodies, where it aims to suppress the immune-mediated destruction of dorsal root ganglion neurons.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide sandoz.